Drawing for PRIAVOID

USPTO serial 79226526

PRIAVOID

Reviewed by CopyMark Law Group

Reg. 5582971Status 709
Filing date
Status date
Registration date
Oct 16, 2018
Examiner
RIEPEL, CHRISTINA MAXINE
Law office
PUBLICATION AND ISSUE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with PRIAVOID?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
001Chemical substances for the production of pharmaceuticals; esters of fatty acids for use in pharmaceuticals; preservatives for pharmaceutical compounds; antimicrobial preservatives for pharmaceutical compounds; chemicals for the preparation being manufacturing and production of pharmaceuticals; antioxidants for the production of pharmaceutical products; chemical compounds for the preparation being manufacturing of pharmaceutical products; esters being viscose chemicals for the production of pharmaceutical products; preservatives for use in the pharmaceutical industry; softening agents being chemical agents for manufacturing for use during the preparation of pharmaceuticals; chemical products for use in the pharmaceutical industry, namely, for use in pharmaceutical manufacturing; active chemical ingredients for the use during the preparation being manufacturing of pharmaceuticals; biochemical compounds for scientific purposes; biochemical products, namely polypeptides for in vitro research applications; biochemical products, namely, chemical reagents for in vitro genetic technology; reagents for use in scientific apparatus for chemical and biological analysis; diagnostic reagents for in vitro use in biochemistry, clinical chemistry and microbiology; biochemicals, namely, monoclonal antibodies for in vitro scientific or research useSECTION 71 - CANCELLED—
005Pharmaceuticals for the prevention and treatment of allergies and for the abatement of burns; drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; pharmaceuticals, namely, anti-infectives, immunostimulants; implantable pharmaceuticals namely, biological tissues grafts; serotherapeutic pharmaceuticals for treatment of meningitis and respiratory disorders; pharmaceutical drugs for treatment of Alzheimer's and dementia; medicated throat sprays; medicine for dental purpose; medicine for veterinary purpose, namely, bacteriostats; medicine for intestinal diseases; pharmaceutical preparations for human purposes, namely, for treatment of Alzheimer's and dementia; pharmaceuticals for the treatment of the autonomic nervous system; pharmaceuticals for the treatment of gastrointestinal diseases; pharmaceutical compounds and products for treatment of Alzheimer's and dementia; chemical and pharmaceutical products and preparations for medical purposes, namely, medical diagnostic reagents; antiepileptic pharmaceutical preparations; pharmaceutical compounds and substances for treatment of Alzheimer's and dementia; chemical compounds for pharmaceutical purpose, namely, for the diagnosis of pregnancy; pharmaceutical agents for metabolism; pharmaceutical agents for treatment of the intestines; pharmaceutical compounds for human use, namely, menstrual symptom treatment preparations; synthetic peptides for pharmaceutical purpose for the prevention and treatment of flu; pharmaceutical agents and compounds for the peripheral nervous system; pharmaceutical products for the treatment of infections; pharmaceutical products for the treatment of hyperlipidemias; crystals for therapeutical purpose being pharmaceutical products, namely, mineral preparations; pharmaceutical compounds for the prevention and treatment of metabolic disorder; pharmaceutical compounds for the treatment of kidney diseases; pharmaceutical compounds for the prevention and treatment of metabolic diseases; chemicals for pharmaceutical use, namely, chemical preparations for the diagnosis of pregnancy; pharmaceutical compounds for the treatment of a chemical imbalance; pharmaceutical preparations for the central nervous system; pharmaceutical compounds for the treatment of diabetes; pharmaceutical compounds for the treatment of Parkinson disease; pharmaceutical compounds for the treatment of multiple sclerosis; pharmaceutical compounds and substances for the prevention of cancer; pharmaceutical compounds and substances with analgesic properties; pharmaceutical compounds for the treatment of epilepsy, disorders of the intestines and of the sensory organs; pharmaceutical compounds for the prevention of disorders and diseases of the nervous system; pharmaceutical compounds and substances for the treatment of cancer and cardiovascular diseases; pharmaceutical compounds and substances for use in oncology; pharmaceutical products and substances for the treatment of gastrointestinal diseases; pharmaceutical compounds for the treatment of diseases of the central nervous system (CNS); biological preparations for treatment of neurological disorders; biological compounds for the treatment of cancer; biochemical compounds for the treatment of cancer and for pain treatment; biotechnological compounds for medical purpose, namely, bioactive pharmaceuticals for treatment of Alzheimer's and dementia; diagnostic biomarker reagents for medical purpose; bio-pharmaceuticals for the treatment of cancerSECTION 71 - CANCELLED—
042Development of pharmaceutical compounds and drugs; research and development of vaccine and drugs; pharmaceutical product development in relation to drugs; pharmaceutical research, research regarding pharmaceuticals; conducting of quality control tests on pharmaceutical products; medical and pharmaceutical research services; pharmaceutical research and development services; pharmaceutical research and development; development of pharmaceutical products; evaluation of results from quality control tests conducted on goods and services in relation to pharmaceutical products; consulting with regard to pharmacology; laboratory research services with regard to pharmaceuticals; research in the field of pharmaceuticals; consulting with regard to pharmaceutical research and development; scientific research in the field of pharmacy; pharmaceutical product evaluation, namely services for the evaluation of the therapeutic effects of pharmaceuticals; research and development services for the pharmaceutical industry; research and development in the field of pharmacy and biotechnology; information technology (IT) consultancy services for pharmaceutical industry and health sector; quality assessment in the nature of quality testing, analysis and evaluation with regard to research in the field of pharmacogenetics; biochemical research; biological research; biological analysis; biological research services; biological development services; biological laboratory services; biochemical analysis; biomedical research; biotechnological research; research regarding biotechnologies; biotechnological research services; scientific research regarding biology; biological research and analysis; research in the field of biotechnology; consulting in the field of biology; consulting in the field of biochemistry; research and development in the field of biochemistry; research and development services in the field of biotechnologySECTION 71 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Aug 20, 2026INNTTOTAL INVALIDATION PROCESSED BY THE IB—
Aug 6, 2026INTSTOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB—
Aug 6, 2026INPCINVALIDATION PROCESSED—
Jan 2, 2026INTRTOTAL INVALIDATION OF REG EXT PROTECTION CREATED—
May 2, 2025C71TCANCELLED SECTION 71—
May 11, 2024NREPNEW REPRESENTATIVE AT IB RECEIVED—
Oct 16, 2023REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Nov 19, 2022NREPNEW REPRESENTATIVE AT IB RECEIVED—
Feb 22, 2019FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Jan 31, 2019FICSFINAL DISPOSITION NOTICE SENT TO IB—
Jan 31, 2019FIMPFINAL DISPOSITION PROCESSED—
Jan 16, 2019FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Oct 16, 2018R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jul 31, 2018NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jul 31, 2018PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jul 27, 2018GPNXNOTIFICATION PROCESSED BY IB—
Jul 11, 2018OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Jul 11, 2018NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jul 11, 2018OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Jul 5, 2018CHLDCHANGE OF OWNER RECEIVED FROM IB—
Jun 21, 2018CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jun 21, 2018TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jun 20, 2018CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jun 20, 2018TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 24, 2018RFNPREFUSAL PROCESSED BY IB—
Mar 6, 2018CNRTNON-FINAL ACTION MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 5, 2018CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 3, 2018RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Mar 2, 2018RFRRREFUSAL PROCESSED BY MPU—
Feb 22, 2018RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Feb 21, 2018CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 16, 2018MAFRAPPLICATION FILING RECEIPT MAILED—
Feb 12, 2018DOCKASSIGNED TO EXAMINER—
Feb 12, 2018NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Feb 8, 2018REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance